Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.52 |
| ▸ | CA2 | P00918 | 5/20 | 0.52 |
| ▸ | CA9 | Q16790 | 5/20 | 0.52 |
| ▸ | CA12 | O43570 | 4/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 2/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.43 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.43 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.42 |
| ▸ | TYMS | P04818 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALPL | P05186 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.40 |
| ▸ | TYMP | P19971 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11161300 | 0.86 | CA1 (0.53) | CA1CA2CA9CA12CASP1 | |
| SCHEMBL57524 | 0.85 | CA1 (0.63) | CA1CA2CA9F2PRSS1 | |
| SCHEMBL31605318 | 0.85 | CA1 (0.63) | CA1CA2CA9F2PRSS1 | |
| SCHEMBL29409606 | 0.85 | CA1 (0.63) | CA1CA2CA9F2PRSS1 | |
| SCHEMBL7127239 | 0.85 | ALDH1A1 (0.48) | CA1CA2CA9CA12MEN1 | |
| SCHEMBL7323070 | 0.84 | CA1 (0.52) | CA1CA2CA9CA12CASP1 | |
| SCHEMBL1584839 | 0.83 | CA1 (0.61) | CA1CA2CA9F2PRSS1 | |
| SCHEMBL1584838 | 0.83 | CA1 (0.61) | CA1CA2CA9F2PRSS1 | |
| SCHEMBL22659705 | 0.83 | CYP17A1 (0.45) | — | |
| SCHEMBL4360130 | 0.82 | CA1 (0.50) | CA1CA2CA9CA12CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108822002-B | Method for synthesizing N-aryl sulfonamide under assistance of ultrasonic waves | 中南大学 | 2020-05-05 | — | — | CN | disclosed |
| US-7528158-B2 | Indazolone derivatives useful as 11b-HSD1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2009-05-05 | — | — | US | disclosed |
| EP-1797042-B1 | INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-01-07 | — | — | EP | disclosed |
| US-20060069269-A1 | Novel indazolone derivatives useful as 11b-HSD1 inhibitors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2006-03-30 | — | — | US | disclosed |
| EP-0932600-B1 | SULFONAMIDE SUBSTITUTED ASPARTIC ACID INTERLEUKIN-1BETA CONVERTING ENZYME INHIBITORS | WARNER LAMBERT CO (US) | 2006-02-08 | — | — | EP | disclosed |
| EP-1263716-A2 | AMINO ACID DERIVATIVES AS HIV ASPARTYL PROTEASE INHIBITORS | Pharmacor Inc. (CA) | 2002-12-11 | — | — | EP | disclosed |
| US-6455587-B1 | AROMATIC SULFONYL DERIVATIVES | PHARMACOR INC. (CA) | 2002-09-24 | — | — | US | disclosed |
| WO-2001068593-A2 | AMINO ACID DERIVATIVES AS HIV ASPARTYL PROTEASE INHIBITORS | PHARMACOR INC. (CA) | 2001-09-20 | — | — | WO | disclosed |
| US-6083981-A | USEFUL FOR TREATMENT OF STROKE, INFLAMMATORY DISEASES, SEPTIC SHOCK, REPERFUSION INJURY, ALZHEIMER'S DISEASE, SHIGELLOSIS | WARNER-LAMBERT COMPANY (US) | 2000-07-04 | — | — | US | disclosed |
| US-6054487-A | ADMINISTERING AN INTERLEUKIN-ONE BETA CONVERTING ENZYME SUFFICIENT TO INHIBIT PRODUCTION OF GAMMA-INTERFERON | BASF AKTIENGESELLSCHAFT (DE) | 2000-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069269-A1 | Novel indazolone derivatives useful as 11b-HSD1 inhibitors | HSD17B1, HSD11B1, HSD17B7 | CA1 2473/4885CA2 2750/4885CA9 1762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.